Over the past several decades, neurofibromatosis type 1 (NF1) has become increasingly recognized as a neurodevelopmental disorder conferring increased risk for several important neurodevelopmental problems. In this review, we summarize the specific neurodevelopmental problems encountered in the context of NF1. These include impairments in general cognitive function, deficits in specific cognitive domains such as executive function and visuospatial processing and risk for specific learning disorders, impairments in attention and social skills and the overlap with attention-deficit-hyperactivity disorder and autism spectrum disorder, and the risk of developing other psychiatric conditions including anxiety and depression. Early recognition of these developmental impairments is important for the effective treatment of children with NF1, and further characterization is essential to improve our understanding of how mutations in the NF1 gene create the diversity of clinical neuropsychiatric symptomatology observed in this at-risk population.
Neurofibromatosis type 1 (NF1) is an autosomal dominant condition caused by mutations in the NF1 gene on chromosome 17q11.2. NF1 is a common neurogenetic disorder, affecting approximately 1 in 3000 people worldwide, 1 exhibiting extreme clinical variability both within and between families. Characterized by specific dermatological findings, such as caf e-au-lait macules skinfold (intertriginous) freckling, and iris hamartomas (Lisch nodules), children and adults are predisposed to the development of multiple benign and malignant tumors. 2 In addition to these clinical findings, NF1 is becoming increasingly recognized as a neurodevelopmental disorder conferring increased risk for several specific neurodevelopmental problems, including lowering of intellectual abilities, deficits in executive functioning, impaired visuospatial processing, and motor delays. Moreover, children with NF1 also harbor increased rates of attention-deficit-hyperactivity disorder (ADHD), impairments in specific academic domains of reading, spelling, and mathematics, difficulties in social functioning with increased rates of autism spectrum disorder (ASD), and elevated rates of other psychiatric conditions (mood and anxiety disorders). Since the underlying biological mechanism(s) of these neurodevelopmental impairments remain incompletely understood, this review will focus on the neurodevelopmental problems encountered in the context of NF1.
NF1 AND IMPAIRMENTS IN INTELLECTUAL ABILITY
Intellectual disability (formerly mental retardation) is defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), as an IQ score of 70 or below with associated impairments in adaptive functioning, 3 and was the first reported cognitive impairment in NF1. Initial estimates of intellectual disability were greatly overestimated in early reports of cognitive function in patients with NF1 owing to the inclusion of only the most severe phenotypes; 2 however, lowered school performance and intellectual functioning were consistently reported, suggesting a mildly affected subset of children not otherwise meeting criteria for intellectual disability. 4, 5 In more recent and larger studies using US National Institutes of Health diagnostic criteria to diagnose NF1, estimates of intellectual disability have varied (4% to 8%), but have remained consistently above that of the general population (3%). 2, 6 While the absolute rates of intellectual disability are only modestly elevated, individuals with NF1 demonstrate a reduction in expected IQ by approximately 1SD relative to both the general population and unaffected siblings, signifying a reduction in intellectual ability in the presence of NF1 gene mutations, despite a shared genetic background and environment. 6 An exception to this 1SD shift in cognitive ability is observed in individuals with the 17q11.2 1.4-megabase NF1 microdeletion syndrome. Over half of these affected individuals have IQs less than 70, constituting a diagnosis of intellectual disability, and nearly all display characteristic facial dysmorphisms. 7 Apart from the well-established genotype-phenotype correlation associated with 17q11.2 1.4-megabase microdeletions, NF1 clinical severity is not a reliable predictor of intellectual ability, and impairment exists even when children with intracranial lesions are excluded from these analyses.
However, children who require treatment for oncological complications of NF1 remain at elevated risk for long-term cognitive and behavioral sequelae typically associated with cranial radiation and chemotherapy. The general reduction in cognitive functioning observed among children with NF1 has the potential to portend significant academic difficulties and result in school failure, thus requiring prompt recognition through comprehensive neuropsychological evaluations, and the early initiation of educational support mechanisms.
SPECIFIC LEARNING DISORDERS AND DOMAIN-SPECIFIC DEFICITS IN COGNITIVE PROCESSING
Nearly 20% of children with NF1 meet criteria for a specific learning disorder, which is more than double that observed in the typically developing pediatric population, 6 although as many as 75% of children with NF1 will require some type of school accommodation or remedial teaching. 8 Specific learning disorders connote substantially lower performance in a particular subject, such as reading (formerly dyslexia), mathematics (formerly dyscalculia), or writing (formerly dysgraphia), that is not otherwise attributable to lower general cognitive ability or comorbid medical conditions, and continue despite targeted intervention. 3 In the DSM-5, there is no requirement for a specific discrepancy between achievement testing in these areas and IQ testing; however, most studies of children with NF1 were performed using DSM-IV criteria, which required a discrepancy between performance and IQ. While early studies often used these more liberal criteria, such as needing special instruction in certain subjects or performance scores in specific subjects, 2,4,5 children with NF1 were disproportionately found to meet criteria for specific learning disorders in reading, mathematics, and writing/spelling, 6 even when accounting for IQ. In addition to specific learning disorders, children with NF1 often have deficits in other specific cognitive domains, including executive functioning and visuospatial processing. Executive function includes aspects of both organization and regulation, specifically with respect to working memory, abstraction, initiation of mental rules or task sets, cognitive flexibility, planning and problem solving, emotional regulation, and attentional control. When directly tested, children with NF1 tend to show deficits in more global measures of executive function, such as problem solving, planning, and task switching. 4, 9 Although executive function has been previously demonstrated to be tightly correlated to general intellectual ability, 6 the observed deficits may represent a core feature of NF1, rather than a resultant effect of lower IQ. 10 Similarly, there is robust evidence to suggest that visuospatial processing is specifically impaired in children with NF1, as evidenced by deficits in the judgment of line orientation test. 4 Subsequent studies investigating alternative spatial judgement tasks, while controlling for motor speed and visual tracking, have continued to demonstrate widespread deficits in visuospatial processing in children with NF1. 6 
ATTENTION PROBLEMS AND OVERLAP WITH ADHD
For more than 30 years, researchers and clinicians have reported significant attentional problems in children with NF1. 5 Over time, it has become increasingly recognized that children with NF1 have specific deficits in attention, 4 particularly in sustained attention. 6 While the exact prevalence varies owing to differences in study methodology, as many as 60% of children with NF1 meet diagnostic criteria for ADHD. 11 Unlike ADHD observed in the general population, children with NF1 rarely meet criteria for hyperactive/impulsive-type ADHD, and are more likely to be diagnosed with either inattentive-type or combined-type ADHD. 11 The relative absence of the hyperactivity phenotype often delays clinical recognition of an impairment in attention system function among children with NF1.
While ADHD is a highly heritable condition, the genetic basis is not well understood. 12 Research into the underlying etiology of ADHD has largely focused on dopaminergic and noradrenergic systems, particularly the striatum 12 given the efficacy of stimulant medication in treating ADHD. While the neurobiology of the attentional deficits in NF1 are also poorly understood, there is some indication in animal studies that these problems reflect changes in dopaminergic function, 13, 14 although given the limited evidence of dopamine dysfunction in humans, the relationship between dopamine and the ADHD phenotype in NF1 remains unclear. 11, 15 Recently, research into the neurobiology of ADHD has turned to understanding deficits in terms of neural network systems, such as the frontal-parietal attention system, thought to be related to task-level attention, and the default mode network, which may be related to both internal reflection and future projection, 16 and potentially more similar to the deficits in sustained attention seen in children with NF1. It is currently not known whether the neurobiological mechanisms responsible for idiopathic ADHD translate to the attentional deficits observed in NF1. 15 However, despite a limited understanding of the potential etiology of ADHD in NF1, it is of critical importance to recognize and treat these symptoms as several studies have now demonstrated the benefit of stimulant medications for the treatment of ADHD in children with NF1.
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SOCIAL DEFICITS AND OVERLAP WITH ASD
Children with NF1 have long been recognized to exhibit social perception problems, although the exact nature of these deficits was not explored until recently. Previously, it had been posited that the social difficulties experienced by What this paper adds
• Impairments in general cognition, executive function, and visuospatial processing are common in children with neurofibromatosis type 1 (NF1).
• Children with NF1 are at high risk for specific learning disabilities involving reading, writing, and math skills.
• Attention-deficit-hyperactivity disorder, autism spectrum disorder, and anxiety are common in children with NF1.
• Early recognition of neurodevelopmental impairments in children with NF1 is critical for initiation of early intervention therapies.
Review 1113 children with NF1 were related to the physical stigmata of NF1. 4 As the comorbidity with ADHD was better appreciated, it was later hypothesized that impairments in attention were contributing to problems with social interactions, as consistently observed in idiopathic ADHD. 19 There is now, however, increasingly strong evidence that children with NF1 have a core deficit in social functioning.
Several recent moderately sized studies, 19, 20 and one large multisite study, 21 have demonstrated an overall decline in social functioning across multiple domains, as well as a substantial increase in the incidence of clincial ASD based on criterion standard diagnostic assessments: approximately 25% to 40% of individuals with NF1, 20, 21 much higher than the 1% to 2% rate of ASD observed in the general population. 21 Moreover, using quantitative measures of ASD symptom severity, the distribution of quantitative ASD traits in NF1 is pathologically shifted towards the more symptomatic end of the spectrum, with nearly 40% of patients scoring within the impaired range. In addition, 13% of children with NF1 score within the most severe range, independent of general cognitive ability. Symptoms in the two domains that characterize ASD (social communication/interaction and restricted interests/ repetitive behaviors) are elevated in patients with NF1-ASD, where these impairments moderately correlate with ADHD symptom severity (Fig. 1) . These findings indicate a similar overall phenotype to idiopathic ASD. [19] [20] [21] However, unlike idiopathic ASD, males and females appear to be similarly affected, suggesting a lessening of the female protective effect for ASD symptoms, similar to other syndromic causes of ASD. 21 The longitudinal trajectory of ASD symptomatology in early childhood and the efficacy of early intensive behavioral interventions in children with NF1-ASD are currently unknown and require further investigation.
MOOD AND ANXIETY DISORDERS IN NF1
Depression and anxiety have long been regarded as important comorbid conditions in adults with NF1; 22 however, the impact of these common psychiatric disorders in childhood is incompletely understood. Studies exploring general measures of quality of life have demonstrated a reduction in quality of life among adults and children with NF1, and recent larger studies have consistently revealed increased rates of depression and anxiety in adults using standardized measures. 22, 23 Studies investigating anxiety/depression symptoms in children with NF1 have generally suggested increased rates of both anxiety and depression, but have relied on relatively small sample sizes and have used varying measurement tools. 19, 24, 25 When investigating factors that mediate well-being and quality of life in children, family influences showed much stronger correlations than measures such as disease severity. 26 Interestingly, when compared with other chronic illnesses, rates of depression reported in adults with NF1 are similar to those found in individuals with multiple sclerosis, diabetes, and coronary artery disease, all of which predispose to intracranial pathology. 23 This observation suggests that the psychiatric manifestations in NF1 may be related to underlying neuropathological changes, rather than being a consequence of social distress related to NF1 disease severity. Interestingly, while the rates of depression are increased in patients with chronic pain, with depression influencing pain and pain influencing depressive symptoms, 27 there was no clear association between ratings of physical complaints 26 or pain 23 and ratings of depression in patients with NF1. Furthermore, while mood and anxiety disorders are thought to be multifactorial in etiology, there is a clear genetic predisposition and neurodevelopmental influence in the development of these conditions, 28 suggesting that the neurodevelopmental sequelae of NF1 (i.e. intellectual disability, ADHD, ASD) may provide additive risk to the development of anxiety and depression in children with NF1.
CONCLUSION
NF1 is a monogenic tumor-predisposition syndrome with varied effects on neural structure and function, creating a wide variety of cognitive and behavioral abnormalities. In this regard, NF1 is associated with an overall decrease in cognitive functioning, with a pathological shift in IQ distribution. In addition, affected individuals exhibit specific deficits in visuospatial processing, attention, and social functioning, which increase the rates of specific learning disorders, ADHD, and ASD. Interestingly, similar neurocognitive impairments have been identified in a related class of developmental disorders caused by germline mutations in genes that affect the Ras/MAPK (mitogenactivated protein kinase) pathway (RASopathies; i.e. Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome), suggesting that dysregulation of this welldefined signal transduction pathway may be critical to the development of cognitive and behavioral dysfunction. 29 Prompt recognition of these developmental and behavioral impairments in children with NF1 is essential for early behavioral and academic interventions and/or timely medical treatment. Further characterization of these neurodevelopmental impairments in children with NF1 and related disorders (currently underway in multiple active international clinical studies) is essential to deepen our understanding of how defects in the NF1 gene and associated genes create the diversity of clinical neuropsychiatric symptomatology observed in this at-risk population.
Additional information about active clinical research studies in NF1 can be found at https://clinicaltrials.gov/.
